TITLE:
Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?
AUTHORS:
Ellen G. Engelhardt, Mieke Kriege, Maartje J. Hooning, Caroline Seynaeve, Rob A. E. M. Tollenaar, Christina J. van Asperen, Margreet G. E. M. Ausems, Lonneke V. van de Poll-Franse, Stella Mook, Senno Verhoef, Matti A. Rookus, HEBON Collaborators, Marjanka K. Schmidt
KEYWORDS:
BRCA1/2, Familial, Breast Cancer, Treatment, Adjuvant Chemotherapy, Mastectomy, Breast Conserving Therapy
JOURNAL NAME:
Advances in Breast Cancer Research,
Vol.4 No.4,
September
30,
2015
ABSTRACT: Objective: It is unclear if and to what extent family history of
breast/ovarian cancer or BRCA1/2-mutation
carriership influences breast cancer treatment strategy. We investigated
whether treatment differed between patients from BRCA1/2 families and those unselected for family history. Methods:
We included 478 BRCA1/2-related
patients referred for genetic testing before or after diagnosis. Two references
were used: 13,498 population-based and 6896 hospital-based patients. Surgical
treatment and adjuvant chemotherapy use was analyzed using logistic regression
models, stratified by tumor size, nodal status, age at and period of diagnosis,
and estrogen receptor status (ER). Results: BRCA1/2
cases aged 35 - 52 years at diagnosis and/or with tumors BRCA1
and ER-negative BRCA1/2-cases
irrespective of age and nodal status (OR 1.9 to 24.3). Conclusion: After 1995
treatment of BRCA1/2-associated
patients consisted notably of more mastectomies and adjuvant chemotherapy than
their population-based counterparts with the same tumor characteristics. There
is a need to be aware of such differences in daily practice and interpretation
of survival studies on BRCA1/2
mutation carriers.